| Dana Gayle Hanebutt, NP | |
|
2508 N Harrison St, Shawnee, OK 74804-3131 | |
| (405) 585-2030 | |
| Not Available |
| Full Name | Dana Gayle Hanebutt |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 6 Years |
| Location | 2508 N Harrison St, Shawnee, Oklahoma |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336612662 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 80049 (Oklahoma) | Secondary |
| 363L00000X | Nurse Practitioner | 80049 (Oklahoma) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Citizen Potawatomi Nation | 3375511488 | 26 |
News Archive
Novadaq® Technologies Inc., a developer of real-time imaging systems for use in the operating room, today announced 2009 third quarter revenues of $1,723,000 compared to revenue of $3,311,000 in third quarter 2008. In accordance with corporate policy, a previously reported order in excess of $2,000,000 has not been recorded in sales due to cash not yet received.
Purdue University scientists found that mice raised in cages may relieve stress with behaviors associated with mice in the wild.
Five Dartmouth College alumni and health care investors have committed a total of $1.4 million in gifts to launch the Dartmouth Innovations Accelerator for Cancer.
For the first time, people with psoriasis and psoriatic arthritis can contribute directly to the future of research into these chronic, systemic autoimmune diseases through the National Psoriasis Foundation's patient-centered research network called Citizen Pscientist.
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced positive results from the pivotal trial of single-agent brentuximab vedotin (SGN-35) in relapsed or refractory Hodgkin lymphoma. Brentuximab vedotin is an antibody-drug conjugate targeted to CD30, a defining marker of Hodgkin lymphoma.
› Verified 6 days ago
| Entity Name | Citizen Potawatomi Nation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881981744 PECOS PAC ID: 3375511488 Enrollment ID: O20140123000876 |
News Archive
Novadaq® Technologies Inc., a developer of real-time imaging systems for use in the operating room, today announced 2009 third quarter revenues of $1,723,000 compared to revenue of $3,311,000 in third quarter 2008. In accordance with corporate policy, a previously reported order in excess of $2,000,000 has not been recorded in sales due to cash not yet received.
Purdue University scientists found that mice raised in cages may relieve stress with behaviors associated with mice in the wild.
Five Dartmouth College alumni and health care investors have committed a total of $1.4 million in gifts to launch the Dartmouth Innovations Accelerator for Cancer.
For the first time, people with psoriasis and psoriatic arthritis can contribute directly to the future of research into these chronic, systemic autoimmune diseases through the National Psoriasis Foundation's patient-centered research network called Citizen Pscientist.
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced positive results from the pivotal trial of single-agent brentuximab vedotin (SGN-35) in relapsed or refractory Hodgkin lymphoma. Brentuximab vedotin is an antibody-drug conjugate targeted to CD30, a defining marker of Hodgkin lymphoma.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dana Gayle Hanebutt, NP Po Box 269031, Oklahoma City, OK 73126-9031 Ph: (405) 585-2030 | Dana Gayle Hanebutt, NP 2508 N Harrison St, Shawnee, OK 74804-3131 Ph: (405) 585-2030 |
News Archive
Novadaq® Technologies Inc., a developer of real-time imaging systems for use in the operating room, today announced 2009 third quarter revenues of $1,723,000 compared to revenue of $3,311,000 in third quarter 2008. In accordance with corporate policy, a previously reported order in excess of $2,000,000 has not been recorded in sales due to cash not yet received.
Purdue University scientists found that mice raised in cages may relieve stress with behaviors associated with mice in the wild.
Five Dartmouth College alumni and health care investors have committed a total of $1.4 million in gifts to launch the Dartmouth Innovations Accelerator for Cancer.
For the first time, people with psoriasis and psoriatic arthritis can contribute directly to the future of research into these chronic, systemic autoimmune diseases through the National Psoriasis Foundation's patient-centered research network called Citizen Pscientist.
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced positive results from the pivotal trial of single-agent brentuximab vedotin (SGN-35) in relapsed or refractory Hodgkin lymphoma. Brentuximab vedotin is an antibody-drug conjugate targeted to CD30, a defining marker of Hodgkin lymphoma.
› Verified 6 days ago